| Myasthenia Gravis, Generalized
Rystiggo vs Uplinza
Side-by-side clinical, coverage, and cost comparison for myasthenia gravis, generalized.Deep comparison between: Rystiggo vs Uplizna with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUplizna has a higher rate of injection site reactions vs Rystiggo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Uplizna but not Rystiggo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rystiggo
Uplizna
At A Glance
SC injection
Once weekly (6-week cycles)
FcRn blocker
IV infusion
Every 6 months
CD19-directed cytolytic antibody
Indications
- Myasthenia Gravis, Generalized
- Neuromyelitis Optica
- Immunoglobulin G4-Related Disease
- Myasthenia Gravis, Generalized
Dosing
Myasthenia Gravis, Generalized Weight-based SC infusion once weekly for 6 weeks: less than 50 kg: 420 mg (3 mL); 50 to less than 100 kg: 560 mg (4 mL); 100 kg and above: 840 mg (6 mL); administer at up to 20 mL/hour; subsequent cycles based on clinical evaluation, no sooner than 63 days from start of previous cycle.
Neuromyelitis Optica, Immunoglobulin G4-Related Disease, Myasthenia Gravis, Generalized Initial dose: 300 mg IV infusion, followed 2 weeks later by a second 300 mg IV infusion; subsequent doses: 300 mg IV infusion every 6 months starting 6 months from first infusion; premedicate with a corticosteroid (methylprednisolone 80-125 mg IV), antihistamine (diphenhydramine 25-50 mg oral), and antipyretic (acetaminophen 500-650 mg oral) before each infusion; dilute in 250 mL 0.9% Sodium Chloride and infuse over approximately 90 minutes.
Contraindications
—
- History of life-threatening infusion reaction to inebilizumab-cdon or any excipient
- Active hepatitis B infection (confirmed by positive HBsAg and anti-HBV tests)
- Active or untreated latent tuberculosis
Adverse Reactions
Most common (>=10%) headache, infections, diarrhea, pyrexia, hypersensitivity reactions, nausea
Serious infections (including fatal pneumonia), aseptic meningitis
Postmarketing herpes zoster
Most common (>=10%) Urinary tract infection, nasopharyngitis, infusion-related reaction, arthralgia, headache, lymphopenia
Serious Infusion reactions, infections, reduction in immunoglobulins
Pharmacology
FcRn antagonist; rozanolixizumab-noli is a humanized IgG4 monoclonal antibody that binds to the neonatal Fc receptor (FcRn), reducing circulating IgG levels and pathogenic AChR and MuSK autoantibody concentrations in patients with generalized myasthenia gravis.
CD19-directed humanized afucosylated IgG1 monoclonal antibody; binds CD19 on pre-B and mature B lymphocytes and induces antibody-dependent cellular cytolysis, depleting B-cell counts within 8 days of infusion.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rystiggo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Uplizna
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Rystiggo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Uplizna
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Rystiggo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Uplizna
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Myasthenia Gravis - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Amgen By Your Side Copay Assistance Program: UpliznaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RystiggoView full Rystiggo profile
UpliznaView full Uplizna profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.